Pharmacokinetic Study of Single and Multiple Dose of PKL-021 Administered Orally to Healthy Subjects

Phase 1

• Conditions: /A submitted trial is conducted on healthy subjects; MedDRA version: 21.1Level: PTClassification code: 10036312Term: Post-traumatic epilepsy Class: 100000004852; MedDRA version: 22.1Level: PTClassification code: 10076982Term: Post stroke epilepsy Class: 100000004852; Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

• Registration Number: CTIS2023-506633-30-00
• Lead Sponsor: Pikralida Sp. z o.o.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2023-07-26
• Study Completion: 2023-12-21
• Last Update Posted: 21 August 2024

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 12

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Main Objective: ;Secondary Objective: ;Primary end point(s):